Published in J Immunol on January 15, 2005
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol (2010) 3.56
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood (2008) 2.22
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci U S A (2010) 2.09
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A (2008) 1.75
Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis (2007) 1.65
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol (2008) 1.58
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood (2008) 1.55
Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol (2011) 1.39
Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest (2010) 1.36
Rituximab resistance. Best Pract Res Clin Haematol (2011) 1.33
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood (2012) 1.28
The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest (2013) 1.27
Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther (2009) 1.26
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol (2006) 1.24
CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.24
Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy. Clin Exp Immunol (2009) 1.23
Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol (2010) 1.21
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs (2010) 1.21
Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med (2009) 1.20
B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest (2012) 1.17
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A (2005) 1.15
Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 1.15
Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection. Immunity (2015) 1.13
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol (2014) 1.13
B cells in autoimmunity. Arthritis Res Ther (2009) 1.13
Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum (2010) 1.13
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol (2012) 1.12
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol (2012) 1.12
T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood (2007) 1.11
Macrophages are critical effectors of antibody therapies for cancer. MAbs (2015) 1.09
B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther (2013) 1.07
Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther (2009) 1.04
A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol (2009) 1.03
B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest (2007) 1.00
B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: A therapeutic approach for APECED patients. Proc Natl Acad Sci U S A (2008) 0.98
Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood (2010) 0.98
Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther (2005) 0.97
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs (2009) 0.97
Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) (2014) 0.96
Rituximab treatment in rheumatoid arthritis: how does it work? Arthritis Res Ther (2009) 0.95
Role of B cells in systemic lupus erythematosus and rheumatoid arthritis. Curr Opin Immunol (2008) 0.93
Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjug Chem (2012) 0.93
Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther (2012) 0.93
Antigenic modulation and rituximab resistance. Semin Hematol (2010) 0.92
Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front Immunol (2013) 0.91
Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol (2014) 0.90
Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol Pharmacol (2014) 0.89
A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol (2006) 0.89
An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus. J Immunol (2011) 0.88
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica (2011) 0.88
Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation. Int J Rheumatol (2010) 0.87
Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche. J Immunol (2014) 0.86
HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. Haematologica (2010) 0.86
Engineered protease-resistant antibodies with selectable cell-killing functions. J Biol Chem (2013) 0.86
Cells of the synovium in rheumatoid arthritis. B cells. Arthritis Res Ther (2007) 0.85
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica (2014) 0.85
IL-4-secreting secondary T follicular helper (Tfh) cells arise from memory T cells, not persisting Tfh cells, through a B cell-dependent mechanism. J Immunol (2015) 0.85
Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr (2007) 0.84
Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J (2010) 0.84
Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs (2009) 0.84
Hormonal milieu at time of B cell activation controls duration of autoantibody response. J Autoimmun (2014) 0.84
The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer (2009) 0.83
A rheumatoid factor paradox: inhibition of rituximab effector function. Arthritis Res Ther (2013) 0.82
Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol (2012) 0.82
Immune surveillance and lymphoid malignancy in immunocompromised host. Am J Blood Res (2013) 0.82
[B-cell-targeted therapy in the treatment of autoimmune diseases]. Z Rheumatol (2009) 0.81
In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice. PLoS One (2010) 0.81
Recovery of an antiviral antibody response following attrition caused by unrelated infection. PLoS Pathog (2014) 0.81
How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis (2005) 0.80
B-cell tolerance in transplantation: is repertoire remodeling the answer? Expert Rev Clin Immunol (2009) 0.80
Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol (2015) 0.80
Follicular B cells in thyroids of mice with spontaneous autoimmune thyroiditis contribute to disease pathogenesis and are targets of anti-CD20 antibody therapy. J Immunol (2013) 0.80
Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases. Clin Exp Immunol (2009) 0.80
Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol (2017) 0.80
Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J (2008) 0.79
Effect of B-cell depletion on coreceptor switching in R5 simian-human immunodeficiency virus infection of rhesus macaques. J Virol (2011) 0.79
Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheumatol (2015) 0.79
B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev (Orlando) (2010) 0.79
Influence of immunoglobulin isotype on therapeutic antibody function. Blood (2016) 0.78
A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency. Onco Targets Ther (2010) 0.78
Memory CD4 T Cells Induce Antibody-Mediated Rejection of Renal Allografts. J Am Soc Nephrol (2016) 0.78
Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice. J Immunol (2014) 0.78
Mechanisms by Which B Cells and Regulatory T Cells Influence Development of Murine Organ-Specific Autoimmune Diseases. J Clin Med (2017) 0.78
CD4 T Cell Help via B Cells Is Required for Lymphopenia-Induced CD8 T Cell Proliferation. J Immunol (2016) 0.77
Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination. J Biol Chem (2015) 0.77
B cell modulation in rheumatology. Curr Opin Pharmacol (2007) 0.77
Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies. Sci Rep (2016) 0.77
The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview. Front Immunol (2016) 0.76
Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion. Am J Transplant (2016) 0.76
The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol (2016) 0.76
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 14.80
Non-canonical inflammasome activation targets caspase-11. Nature (2011) 8.85
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (2002) 8.63
A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature (2012) 8.10
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res (2008) 5.42
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 5.10
Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science (2013) 5.06
Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity (2002) 4.87
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
T cell receptor signaling precedes immunological synapse formation. Science (2002) 4.56
Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell (2009) 4.52
Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol (2006) 4.20
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med (2002) 4.00
PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science (2008) 3.86
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol (2009) 3.85
Crystal structure of a lipid G protein-coupled receptor. Science (2012) 3.78
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol (2005) 3.70
Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst (2005) 3.58
Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem (2004) 3.57
The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat Immunol (2009) 3.44
PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science (2004) 3.34
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A (2011) 3.20
A specificity map for the PDZ domain family. PLoS Biol (2008) 3.16
Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature (2008) 3.14
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13
A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol (2010) 3.09
Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell (2011) 3.03
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00
S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol (2005) 2.98
CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell (2006) 2.89
Requirement for coronin 1 in T lymphocyte trafficking and cellular homeostasis. Science (2006) 2.85
Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 2.83
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 2.77
Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol (2010) 2.71
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68
Limb remote ischemic preconditioning attenuates lung injury after pulmonary resection under propofol-remifentanil anesthesia: a randomized controlled study. Anesthesiology (2014) 2.66
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol (2006) 2.49
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45
Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med (2009) 2.42
Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res (2006) 2.40
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol (2006) 2.32
Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci (2005) 2.31
Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination. Blood (2011) 2.28
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene (2005) 2.24
Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest (2007) 2.19
Regulation of a late phase of T cell polarity and effector functions by Crtam. Cell (2008) 2.18
In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest (2007) 2.18
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 2.10
A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A (2006) 2.08
A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci U S A (2009) 2.04
The Rad51/RadA N-terminal domain activates nucleoprotein filament ATPase activity. Structure (2006) 2.00
IgE⁺ memory B cells and plasma cells generated through a germinal-center pathway. Nat Immunol (2012) 2.00
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res (2006) 1.99
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res (2010) 1.98
Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann Neurol (2010) 1.96
The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One (2011) 1.96
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol (2011) 1.95
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci (2003) 1.94
Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database Syst Rev (2013) 1.91
PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol (2008) 1.91
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost (2005) 1.86
Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes. Nat Biotechnol (2009) 1.84
Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A (2006) 1.81
The role of receptor internalization in CD95 signaling. EMBO J (2006) 1.80
Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity (2004) 1.79
IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with Citrobacter rodentium. Nat Immunol (2011) 1.78